This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, J. Articles by Mullen, C. A. Search for Related Content PubMed PubMed Citation Articles by Wang, J. Articles by Mullen, C. A.

Down-Regulation of Antihost Alloreactivity after Bone Marrow Transplant Permits Relapse of Hematological Malignancy¹

Departments of Pediatrics [J. W., J. L. S., C. A. M.] and Immunology [C. A. M.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Relapse of leukemia remains a common event after allogeneic bone marrow transplantation, despite potential donor antihost alloreactivity present in most transplants. This work examined posttransplant relapse of the DBA/2 P815 mastocytoma in a murine model of MHC-matched, minor histocompatibility antigen (mHAg)-mismatched bone marrow transplantation (BALB/c donors into DBA/2 recipients). Antihost alloreactivity was associated with reduction of posttransplant tumor burden and prolongation of survival, but posttransplant relapse commonly occurred. No evidence of acquired resistance to immune control was found in 12 relapse reisolates. Relapse tumors remained sensitive to donor antihost CTLs in vitro, suggesting continued expression of mHAgs. Reisolates also continued to express Fas. However, loss of posttransplant alloreactivity was observed at 3 weeks. This was temporally associated with the time of relapse. Antihost alloreactivity could be reactivated in stable graft-versus-host disease-free recipients by immunization with host cells. The results of this study suggest that one mechanism for relapse after bone marrow transplant is acquired tolerance of allogeneic minor histocompatibility antigens and that posttransplant immunotherapy directed against mHAgs may induce antitumor activity.

This article has been cited by other articles:

				G. S. D. Reid, K. She, L. Terrett, M. R. Food, J. D. Trudeau, and K. R. Schultz CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response Blood, May 1, 2005; 105(9): 3641 - 3647. [Abstract] [Full Text] [PDF]

				M.-C. Meunier, G. Roy-Proulx, N. Labrecque, and C. Perreault Tissue distribution of target antigen has a decisive influence on the outcome of adoptive cancer immunotherapy Blood, January 15, 2003; 101(2): 766 - 770. [Abstract] [Full Text] [PDF]